Evaluation of genetic mutations associated with mycobacterium tuberculosis resistance to isoniazid, rifampicin (MTBDR plus), fluoroquinolone and injectable second-line drugs (MTBDRsl)  by Margaryan, Hasmik
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 4 9 –5 0
.sc ienced i rec t .comHO ST E D  BY Avai lab le a t wwwScienceDirect
journal homepage: www.elsevier .com/ locate / IJMYCOEvaluation of genetic mutations associated with
mycobacterium tuberculosis resistance to isoniazid,
rifampicin (MTBDR plus), fluoroquinolone and
injectable second-line drugs (MTBDRsl)http://dx.doi.org/10.1016/j.ijmyco.2014.09.012
2212-5531/ 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.
* Corresponding author. Tel.: +374 98475600.
E-mail address: haso85@mail.ruHasmik Margaryan *
MOH ‘‘National TB Control Center’’ SNPO Yerevan, Margaryan 6/2, ArmeniaA R T I C L E I N F O
Article history:
Received 16 September 2014
Accepted 23 September 2014
Available online 31 October 2014
Keywords:
Epidemiological data
Multidrug and extensively drug
resistance
Tuberculosis
MutationA B S T R A C T
Aims and objectives: Tuberculosis (TB) is one of the major public health problems in
Armenia. In 2009, TB incidence in Armenia was reported to be as high as 45.5 per 100,000
population, and TB mortality was 3.9 per 100,000 population. Only 35% of estimated new
sputum smear-positive pulmonary TB patients are notified annually. From 1729 TB cases
notified in 2010, only 329 patients were sputum smear-positive. The treatment success rate
of new sputum smear-positive pulmonary TB patients was 76%, which is below the WHO
target of 85%. Poor treatment outcome is partially explained by the high prevalence of drug
resistant forms of TB. According to the 2007 drug resistance survey, MDR-TB among
never-treated patients was 9.4% and 43.2% among previously treated cases with 4% of
XDR cases. This represents an enormous public health challenge for Armenia; early
identification and effective treatment of patients with MDR-TB is crucial to prevent further
spread of the disease.
Methods: A total of 583 specimens are sent to the NRL Armenia being either acid-fast
bacterium positive or negative, but culture positive. Rifampin and isoniazid resistance
was performed on 77 out of the 583 specimens of DR TB clinical isolates to analyze
resistance for FQL, AM/CP and EMB.
The DNA preparation method used was as described and recommended by the manufac-
turer (MTBDR plus version 1.0 and MTBDR sl version 2.0 Hain Lifescience, Nehren).
For 99 (88.4%) and 160 (76.2%) strains, the mutations causing rifampicin and isoniazid
resistance were located in the codon of rpoB S531L and katG S315T 1, respectively. Regard-
ing isoniazid, 14 (6.6%) strains have a mutation in the inhA regulatory region (C15T) and 31
(14.7%) in both katG and InhA.
Mutations detected in the FQ, EMB and rrs-resistant respectively are: 13 (16.9%) strains
with the majority of mutations (10 [13%]) in the codon of 94 of the gyrA gen; 20 (26%)
strains, with the majority of mutations (7 [9.1%]) in the codon of 306 of the EMB gen; and
13 (16.8%) strains with the majority of mutations (9 [11.6%]) in the codon of 1401 of the
rrs gen.
Comparing with phenotypically DST sensitivity and specificity for RMP was 97.6% (69
strains) and 100%, respectively. False resistance was detected for 2 strains containing
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98.33%, 87.5% (69 strains). From 2 strains, 1 was false resistant (missing of WT 1, 2 bands)
and 1 false sensitive results for INH. The sensitivity and specificity for AM/CM was 80%,
100%, and for the FQL 85.7%, 96.72%, respectively (69 strains).
Conclusion: Rapid and accurate detection of resistance to first- and second-line anti-TB
drugs is the key to successful therapy and interruption of the transmission chain of MDRTB
strains. In summary, this data represent an important addition to the rare epidemiological
data concerning resistance patterns of MTB in Armenia and showed that the application of
the GenoType MTBDRplus and GenoType MTBDRsl assays might be useful additional tools
to allow for a rapid and safe diagnosis of MDR and XDR TB. In mutations associated with
katG, high dosages of isoniazid in future will be considered for treatment.
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